Corbus Pharmaceuticals(CRBP) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update • Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancer • CRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial cancer and other nectin-4 enriched tumors and is on schedule for completion in Q4 2024 • Cash runway extended throu ...